David R. Gastfriend M.D.
David R. Gastfriend, MD.,
is a Scientific Advisor at TRI and an addiction psychiatrist who completed his training at Massachusetts General Hospital (MGH). Throughout a 25-year span at Harvard Medical School and MGH he was Director of the MGH Addiction Research Program and founded the MGH/McLean Hospital Addiction Psychiatry Fellowship. His pharmacologic and behavioral research activities included serving as an investigator in the National Institute on Drug Abuse (NIDA) Cocaine Collaborative Study, and as investigator and committee chair in the National Institute on Alcohol Abuse and Alcoholism (NIAAA) COMBINE Study and the NIDA Clinical Trials Network. As the lead researcher on the American Society of Addiction Medicine’s (ASAM’s) Patient Placement Criteria, his efforts to operationalize and validate contributed to its endorsement by most U.S. states, the Veterans Administration and the Department of Defense. Dr. Gastfriend is also the Chief Architect of the ASAM Criteria Software, developed with the support of the U.S. Substance Abuse and Mental Health Services Administration for nationwide release.
From 2004 to 2013, Dr. Gastfriend served as Vice President for Scientific Communications at Alkermes, Inc., where he directed scientific publications and presentations on clinical and health economic research in addiction. Dr. Gastfriend has more than 150 scientific publications including The ASAM Criteria
and Addiction Treatment Matching books.
He has advised the governments of China, Iceland, Israel, Norway, Russia and the U.S. on advances in alcohol and drug addiction treatment.
Dr. Gastfriend has received numerous awards including the NIDA Mid-Career Investigator Award for Patient-Oriented Research in 2000; the “Champion in Health Care – Innovator Award” from the Boston Business Journal for his research on Vivitrol®
in 2007; and the ASAM’s McGovern Award and Lecture for contributions to addiction treatment and society.